Inceptor Bio is engaging with top-tier universities that have disruptive cell and gene therapy research programs focused on oncology.
The cell and gene therapy market has grown incredibly quickly in a short number of years and continues to attract incredible interest and investment. The segment is progressively maturing and now benefits from established proof of principle, a robust clinical pipeline, and ample public and private funding. Despite these advances, difficult-to-cure cancers remain a societal burden with poor treatment options available and there are still hurdles for the industry to overcome, such as the following:
Patients relapsing from approved CAR-T therapies
Approval of only hematological oncology indications so far
The complex challenge of reimbursement considerations (costs)
Minimal progress in combating solid tumors
Limitations in manufacturing capacity
Inceptor Bio is focused on multiple specific cell and gene therapy technology platforms:
Immunotherapy in which T cells are engineered to identify and kill cancer cells. There are multiple CAR-T therapies that have gained FDA approval.
CAR-Ms have the ability to access solid tumors, survive in their hostile environment, selectively destroy cancer cells, and activate an adaptive immune response by presenting engulfed tumor material.
NK cells are engineered to identify and attack cancer. Safety (avoiding GvHd) and accessibility (allogeneic) are two strong advantages.
Engineered T cell receptor (TCR) therapy is an approach that involves taking T cells from patients and modifying their most important receptors to recognize and be activated by tumor cells.
Gamma Delta T cells (γδ T Cells) are a unique subset of T-cells with advantages in how they activate and migrate through tissues, providing potential advantages for therapeutics.
Cells utilize RNAi to regulate gene expression and a multitude of vital biological processes.
Adeno-associated virus (AAV) is a viral vector used to deliver cell and gene therapeutics.
Non-viral gene delivery method with the advantages of larger payloads, flexibility of design, ease of manufacturing, reduced immune responses, and multi-dosing capabilities.
A type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living cell, either in vivo or ex vivo.
Inceptor Bio is committed to translational R&D with a focus on validated targets with a known mechanism of action (MOA) and well-understood delivery and trafficking. We are eager to partner with research programs with relevant targets that fall into these categories. Our current cell therapy platforms possess unique co-stimulatory properties and our Advanced Manufacturing Platform (AMP+) provides certainty in access to clinical trial materials. With these synergistic combinations and our purpose-driven cell and gene therapy team, we can focus on advancing novel therapies targeting difficult-to-treat cancers.
Inceptor Bio has engaged with many top universities having programs with novel targets that are being evaluated. Our primary focus is currently in areas of high unmet need, such as solid tumors. While these indications are of primary interest, we are interested in collaborating in additional indications as would be suitable for additional targeting moieties.